Premium
Donepezil in the treatment of progressive supranuclear palsy
Author(s) -
Fabbrini G.,
Barbanti P.,
Bonifati V.,
Colosimo C.,
Gasparini M.,
Vanacore N.,
Meco G.
Publication year - 2001
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1034/j.1600-0404.2001.103002123.x
Subject(s) - donepezil , progressive supranuclear palsy , galantamine , psychology , cognition , medicine , physical medicine and rehabilitation , activities of daily living , bedtime , cholinesterase , pediatrics , physical therapy , dementia , psychiatry , disease
Objectives – To evaluate the effect of 3 month therapy with donepezil, a centrally acting cholinesterase inhibitor, on cognitive performances, motor function and daily living activities in progressive supranuclear palsy (PSP). Materials and methods – Six patients with a diagnosis of PSP were evaluated at baseline and after 3 months of treatment with donepezil, 10 mg given at bedtime. Cognitive functions, motor symptoms and daily activities were evaluated by means of appropriate rating scales. Results – Donepezil was not effective on cognitive dysfunction and did not change ratings of daily living. Parkinsonian symptoms were unaffected by donepezil treatment. Conclusions – Cholinergic replacement therapy alone is not likely to improve symptoms in a disorder characterized by a more widespread impairment of monoaminergic systems. Larger studies may be necessary to confirm the lack of effect of donepezil in this disorder.